Join the 'Rebif Rebidose' group to help and get support from people like you.
Rebif Rebidose News
Posted 7 Oct 2015 by Drugs.com
WEDNESDAY, Oct. 7, 2015 – Multiple sclerosis patients taking a new drug experienced fewer relapse rates but more side effects than patients receiving a standard MS therapy, new research indicates. In a trial comparing two sets of more than 900 patients with relapsing-remitting multiple sclerosis, scientists found that those taking the drug daclizumab HYP had a 45 percent lower relapse rate than ...